Review article: Exploration of the genetic aetiology of inflammatory bowel disease - Implications for diagnosis and therapy

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 20, Issue 4, 2004, Pages 1-8

  Schreiber, S ^a   Hanpe, J ^a   Nikolaus, S ^a   Foelsch, U R ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CROHN DISEASE; DLGS GENE; ENTERITIS; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; LEUKOPENIA; NOD2 GENE; OCTN 1 GENE; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW;

GASTROINTESTINAL AGENTS; GENOME, HUMAN; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 4844227168     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Lauritsen K, Rune SJ, Bytzer P, et al. Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial. N Engl J Med 1985: 312: 958-61.
2. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997: 337: 1029-35.
3. Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997; 349: 521-4.
4. Nikolaus S, Raedler A, Sfikas N, Kühbacher T, Fölsch UR, Schreiber S. Mechanisms in failure of infliximab for Crohn's disease. Lancet 2000: 356: 1475-9.
5. Baert FJ, Rutgeerts PR. Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indications. Int J Colorectal Dis 1999; 14: 47-51.
6. D'Haens GR, Aerden I, van Hogezand R, et al. Duration of response following cessation of infliximab therapy for active or fistulizing Crohn's disease. Gastroenterology 1999; 116: G3029.
7. Scallon BJ, Moore MA, Trinh DM, Ghrayeb J. Chimeric anti-TNF-α monoclonal antibody, cA2, binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 1995; 7: 251-9.
8. Bauditz J, Haemling J, Ortner M, et al. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut 1997; 40: 470-4.
9. Schreiber S, Hampe J. Genetics in gastrointestinal disease: how much can we learn from molecular analysis? Int J Colorectal Dis 1999; 14: 10-2.
10. Hugot JP, Zouali H, Lesage S, et al. Etiology of the inflammatory bowel diseases. Int J Colorectal Dis 1999; 14: 2-9.
11. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-6.
12. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603.
13. Hampe J, Cuthbert A, Croucher P, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001; 357: 925-8.
14. Stoll M, Corneliussen B, Costello CM, et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet 2004; 36: 476-80.
15. Peltekova VD, Wintle RF, Rubin LA, et al. Functional variants of OCTN cation transporter genes are associated with Crohn's disease. Nat Genet 2004; 36: 471-75.
16. Casellas F, Guarner F, Antolin M, et al. Abnormal leukotriene C4 released by unaffected jejunal mucosa in patients with inactive Crohn's disease. Gut 1994; 35: 517-22.
17. Rachmilewitz D, Stamler JS, Karmeli F, et al. Peroxynitrite-induced rat colitis - a new model of colonic inflammation. Gastroenterology 1993; 105: 1681-8.
18. Noronha-Blob L, Lowe VC, Muhlhauser RO, et al. NPC 15669, an inhibitor of neutrophil recruitment, is efficacious in acetic acid-induced colitis in rats. Gastroenterology 1993; 104: 1021-9.
19. Lauritsen K, Laursen LS, Bukhave K, et al. In vivo effects of orally administered prednisolone on prostaglandin and leucotriene production in ulcerative colitis. Gut 1987; 28: 1095-9.
20. Hawkey CJ, Dube LM, Rountree LV, et al. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group for Ulcerative Colitis. Gastroenterology 1997: 112: 718-24.
21. Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995: 270: 286-90.
22. Scheinman RI, Cogswell PC, Lofquist AK, et al. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283-6.
23. Schreiber S, MacDermott RP, Raedler A, et al. Increased activation of isolated intestinal lamina propria mononuclear cells in inflammatory bowel disease. Gastroenterology 1991; 101: 1020-30.
24. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, et al. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 1996; 2: 998-1004.
25. Schottelius AJ, Baldwin AS Jr. A role for transcription factor NF-kappa B in intestinal inflammation. Int J Colorectal Dis 1999; 14: 18-28.
26. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B in inflammatory bowel disease. Gut 1998; 42: 477-84.
27. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75: 263-74.
28. Eynon EE, Flavell RA. Walking through the forest of transgenic models of human disease. Immunol Rev 1999; 169: 5-10.
29. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399-408.
30. Adams MD, Dubnick M, Kerlavage AR, et al. Sequence identification of 2,375 human brain genes. Nature 1992; 355: 632-4.
31. Schuler GD, Boguski MS, Stewart EA, et al. A gene map of the human genome. Science 1996; 274: 540-6.
32. Hugot JP, Laurent-Puig P, Gower-Rousseau C, et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996; 379: 821-3.
33. Curran ME, Lau KF, Hampe J, et al. Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16. Gastroenterology 1998; 115: 1066-71.
34. Brant SR, Fu Y, Fields CT, et al. American families with Crohn's disease have strong evidence for linkage to chromosome 16 but not chromosome 12. Gastroenterology 1998; 115: 1056-61.
35. Annese V, Latiano A, Bovio P, et al. Genetic analysis in Italian families with inflammatory bowel disease supports linkage to the IBD1 locus - a GISC study. Eur J Hum Genet 1999; 7: 567-73.
36. Cavanaugh J & Consortium T.I.I.G. International collaboration provides convincing linkage replication in complex disease through analysis of a large pooled data set. Crohn disease and chromosome 16. Am J Hum Genet 2001: 68: 1165-71.
37. Ohmen JD, Yang HY, Yamamoto KK, et al. Susceptibility locus for inflammatory bowel disease on chromosome 16 has a role in Crohn's disease, but not in ulcerative colitis. Hum Mol Genet 1996; 5: 1679-83.
38. Parkes M, Satsangi J, Lathrop GM, Bell JI, Jewell DP. Susceptibility loci in inflammatory bowel disease. Lancet 1996; 348: 1588.
39. Cho JH, Nicolae DL, Gold LH, et al. Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between lp and IBD1. Proc Acad Polit Sci 1998; 95: 7502-7.
40. Zouali H, Chamaillard M, Lesage S, et al. Genetic refinement and physical mapping of a chromosome 16q candidate region for inflammatory bowel disease. Eur J Hum Genet 2001; 9: 731-42.
41. Brant SR, Panhuysen CI, Bailey-Wilson JE, et al. Linkage heterogeneity for the IBD1 locus in Crohn's disease pedigrees by disease onset and severity. Gastroenterology 2000; 119: 1483-90.
42. Inohara N, Nunez G. The NOD: a signaling module that regulates apoptosis and host defense against pathogens. Oncogene 2001; 20: 6473-81.
43. Rosenstiel P, Fantini M, Bräutigam K, et al. TNF-α and IFN-γ regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology 2003; 124: 1001-9.
44. Hisamatsu T, Suzuki M, Reinecker HC, Nadeau WJ, McCormick BA, Podolsky DK. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003; 124: 993-1000.
45. Cuthbert AP, Fisher SA, Mirza MM, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 2002; 122: 867-74.
46. Ogura Y, Inohara N, Benito A, et al. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 2001; 276: 4812-8.
47. Beutler B. Autoimmunity and apoptosis: the Crohn's connection. Immunity 2001; 15: 5-14.
48. Croucher PJP, Mascheretti S, Hampe J, et al. Haplotype structure and association to Crohn's disease of CARD15 mutations in two ethnically divergent populations. Eur J Hum Genet 2003; 11: 6-16.
49. Hampe J, Grebe J, Nikolaus S, et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 2002; 359: 1661-5.
50. Lesage S, Zouali H, Cezard JP, et al. CARO15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002; 70: 845-57.
51. Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002: 123: 679-88.
52. Ahmad T, Armuzzi A, Bunce M, et al. The molecular classiflcation of the clinical manifestations of Crohn's disease. Gastroenterology 2002: 122: 854-66.
53. Radlmayr M, Torok HP, Martin K, Folwaczny C. The c-insertion mutation of the NOD2 gene is associated with fistulizing and fibrostenotic phenotypes in Crohn's disease. Gastroenterology 2002; 122: 2091-2.
54. Vermeire S, Wild G, Kocher K, et al. CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. Am J Hum Genet 2002; 71: 74-83.
55. Wakabayashi M, Ito T, Mitsushima M, et al. Interaction of Ipdlg/KIAA0583, a membrane-associated guanylate kinase family protein, with vinexin and beta-catenin at sites of cell-cell contact. J Biol Chem 2003; 278: 21709-14.
56. Rioux JD, Daly MJ, Silverberg MS, et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat Genet 2001; 29: 223-28.
57. Giallourkis C, Stoll M, Miller K, et al. IBD5 is a general risk factor for inflammatory bowel disease: replication of association with Crohn's disease and identification of a novel association with ulcerative colitis. Am J Hum Genet 2003; 73: 205-11.
58. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 249-66.
59. van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 1997; 113: 383-9.
60. Drazen JM, Yandava CN, Dube L, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999; 22: 168-70.
61. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterlogy 1999; 117: 761-9.
62. Plevy SE, Taylor K, DeWoody KL, Schaible TF, Shealy D, Targan SR. Tumor necrosis factor (TNF) microsatellite haplotypes and perinuclear anti-neutrophil cytoplasmic antibody (pANCA) identify Crohn's disease (CD) patients with poor clinical responses to anti-TNF monoclonal antibody (cA2). Gastroenterology 1997; 112: A2925(Abstract).
63. Mascheretti S, Hampe J, Kühbacher T, et al. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J 2002: 2: 127-36.
64. Mascheretti S, Hampe J, Croucher PJ, et al. Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics 2002; 12: 509-15.
65. Vermeire S, Louis E, Rutgeerts P, et al. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology 2002; 123: 106-11.
66. ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002; 50: 206-11.
67. Lügering A, Schmidt M, Lügering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001; 121: 1145-57.
68. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124: 1774-85.
69. Waetzig GH, Rosenstiel P, Nikolaus S, et al. Differential p38 mitogen-activated protein kinase targets phosphorylation in responders and nonresponders to infliximab. Gastroenterology 2003; 125: 633-4.
70. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77: 847-69.
71. Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 215-9.
72. Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998; 129: 716-8.
73. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-30.
74. Kader HA, Wenner WJ, Telega GW, Maller ES, Badassano RN. Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease. J Clin Gastroenterol 2000; 30: 409-13.
75. Spire-Vayron de la Moureyre C, Debuysere H, Mastain B, et al. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br J Pharmacol 1998; 125: 879-7.
76. Terwilliger JD, Ott J. A novel polylocus method for linkage analysis using the lod-score or affected sib-pair method. Genet Epidemiol 1993; 10: 477-82.